Group 1 - The core viewpoint of the announcement is the approval of using raised funds to replace self-raised funds for investment projects and issuance expenses, which complies with relevant regulations [1][2] - The supervisory board meeting was held on September 4, 2025, with all three supervisors participating in the voting process [1] - The proposal to reappoint the auditing firm for the year 2025 was also approved unanimously by the supervisory board [2] Group 2 - The supervisory board confirmed that the use of raised funds for replacing self-raised funds was conducted following necessary approval procedures and did not harm shareholder interests [2] - The voting results for both proposals were 3 votes in favor, with no abstentions or oppositions [2]

证券代码：002716 证券简称：湖南白银 公告编号：2025-060 湖南白银股份有限公司 湖南白银股份有限公司监事会 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 湖南白银股份有限公司（以下简称"公司"）第六届监 事会第九次会议通知于 2025 年 9 月 4 日以电话和专人送达 的方式发出，于 2025 年 9 月 4 日上午 11：00 在郴州市苏仙 区白露塘镇福城大道 1 号 316 会议室以现场方式召开。会议 应出席监事 3 人，实际出席会议的监事共 3 人。 会议由吕英翔先生主持。本次会议符合《中华人民共和 国公司法》《中华人民共和国证券法》等有关法律、法规、 规章及《公司章程》的规定。本次会议通过了如下议案： 一、《关于调整公司回购股份价格上限的议案》 内容:公司《关于调整公司回购股份价格上限的公告》 刊登于 2025 年 9 月 5 日的《中国证券报》《上海证券报》 《 证 券 时 报 》 《 证 券 日 报 》 及 巨 潮 资 讯 网 （ http ： //www.cninfo.com.cn）。 表决结果：3 票同意，0 票反对，0 票弃 ...

Core Points - The company is holding a shareholders' meeting on September 12, 2025, to discuss various proposals, including increasing the foreign exchange hedging limit and revising the company's articles of association [3][4][5]. Meeting Rules - The meeting will ensure the protection of shareholders' rights and maintain order and efficiency [1][2]. - Attendees must present valid identification and may need to register in advance if they wish to speak [1][2]. - Voting will be conducted by a named ballot, with each share representing one vote [2][3]. Proposals - Proposal 1: Increase the foreign exchange hedging limit from $1 billion to $1.9 billion to address rising hedging needs due to currency fluctuations [4][5][9]. - Proposal 2: Abolish the supervisory board, transferring its responsibilities to the audit committee of the board of directors, and amend the articles of association accordingly [5][6][7]. - Proposal 3: Revise certain internal regulations to enhance corporate governance and operational efficiency [8][9]. Financial Derivatives Trading - The company plans to engage in foreign exchange derivatives trading to mitigate risks associated with currency fluctuations, with a focus on operational hedging strategies [8][9][10]. - The trading will be funded through the company's own or raised funds, and will not involve speculative activities [10][11]. - A comprehensive risk management framework has been established to oversee the derivatives trading activities [12][13].

Core Points - The company is holding its second extraordinary general meeting of shareholders in 2025 to ensure the rights of all shareholders and the orderly conduct of the meeting [1][2] - The meeting will include voting on key proposals, including the reappointment of the accounting firm and amendments to the company's articles of association [5][6] Meeting Procedures - All attendees must comply with legal obligations to maintain the rights of shareholders and the order of the meeting [1] - Only authorized personnel, including shareholders, directors, supervisors, and legal representatives, are allowed to attend the meeting [2] - Shareholders must sign in 30 minutes before the meeting and present necessary identification documents [3] - Voting will be conducted both on-site and online, with each share carrying one vote [5][6] Agenda Items - Proposal One: Reappointment of Zhongxinghua Accounting Firm as the auditor for the fiscal year 2025, which has been approved by the board's audit committee [6] - Proposal Two: Cancellation of the supervisory board and amendments to the company's articles of association to enhance corporate governance [7][8]

Group 1 - The company has decided to abolish the supervisory board, transferring its responsibilities to the audit committee of the board of directors [1][2] - The proposal to cancel the supervisory board and abolish the relevant rules has been approved by the supervisory board and will be submitted to the shareholders' meeting for review [2] - The company plans to revise its articles of association in accordance with relevant laws and regulations, and will seek authorization from the shareholders' meeting for necessary registration changes [2] Group 2 - The supervisory board's responsibilities will remain in effect until the shareholders' meeting reviews the proposal [2] - The proposal does not involve related party transactions and does not require abstention from voting [2] - The company has disclosed the details of the proposed amendments to the articles of association on the Beijing Stock Exchange information disclosure platform [2]

证券代码： 605289 证券简称： 罗曼股份 公告编号： 2025-047 上海罗曼科技股份有限公司 关于召开2025年第二次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 召开的日期时间：2025 年 9 月 22 日 15 点 00 分 召开地点：上海市杨浦区杨树浦路 1198 号山金金融广场 B 座 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 9 月 22 日 至2025 年 9 月 22 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 (六)融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者 的投票，应按照《上海证券交易所上市公司自律 ...

Core Viewpoint - The legal opinion letter from Beijing Jindu Law Firm Shanghai Branch confirms that the second extraordinary general meeting of shareholders of Shaanxi Kanghui Pharmaceutical Co., Ltd. scheduled for September 4, 2025, complies with relevant laws and regulations [1][4]. Group 1: Meeting Procedures - The meeting is scheduled for September 4, 2025, and the notice has been published in multiple financial newspapers and the Shanghai Stock Exchange website [5]. - The meeting will be held at the company's conference room, presided over by Chairman Wang Yanling, with specific voting times outlined for both in-person and online participation [5][6]. - The legal opinion confirms that the procedures for convening and holding the meeting are in accordance with applicable laws, regulations, and the company's articles of association [5][7]. Group 2: Attendance and Voting - A total of 104 participants attended the meeting, representing 44,758,537 shares, which is 44.8123% of the total voting shares [6][7]. - The online voting system recorded participation from 98 shareholders, representing 1,342,300 shares, or 1.3439% of the total voting shares [6]. - The qualifications of the attendees and the convenor of the meeting were verified and found to be compliant with legal requirements [7]. Group 3: Voting Results - The meeting passed several resolutions with significant support, including votes of 44,588,937 shares (97.2346%) for one of the resolutions, indicating strong shareholder approval [8][10]. - The voting results for the election of directors showed overwhelming support, with votes ranging from 43,467,995 to 43,599,792 shares, all exceeding 97% approval [10][11][12]. - The legal opinion concludes that the voting procedures and results are valid and comply with relevant laws and regulations [13].

Meeting Overview - The shareholders' meeting of Xi'an Kanghui Pharmaceutical Co., Ltd. was held on September 4, 2025, at the company's conference room in Xi'an [1] - The meeting was conducted in accordance with the Company Law and the Articles of Association, combining on-site and online voting methods [1] Attendance and Voting Results - The meeting had a high attendance rate, with A-share shareholders voting overwhelmingly in favor of the proposals, achieving over 99.6% approval for multiple resolutions [1][2] - Specific voting results included: - 44,588,937 votes in favor (99.6210%), 24,500 against (0.0547%), and 145,100 abstentions (0.3243%) for the first resolution [1] - 44,590,237 votes in favor (99.6239%), 2,200 against (0.0049%), and 166,100 abstentions (0.3712%) for the second resolution [2] Resolutions Passed - All non-cumulative voting resolutions were approved, including the election of several directors to the sixth board of directors [3] - The resolutions included the election of Li Hongming, Wang Xiuying, Ma Wenjun, Wang Yanling, Yang Jin, Cui Xuegang, Chen Ying, and Dou Jianwei as directors [3] Legal Compliance - The meeting's procedures were verified by legal counsel, confirming compliance with relevant laws and regulations, ensuring the legitimacy of the meeting and the validity of the voting results [3]

证券代码：688639 证券简称：华恒生物 公告编号：2025-042 安徽华恒生物科技股份有限公司 关于召开2025年第二次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 9 月 23 日14 点 00 分 召开地点：合肥市高新区长安路 197 号公司 A1 会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 9 月 23 日 至2025 年 9 月 23 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的 ...

Group 1 - The company plans to acquire a 50.6329% stake in Wuzhong Yiwang Juice Co., Ltd. due to strategic development needs, which was approved by the board of directors [1][2] - The financial assistance provided to Xi'an Chunguang Beverage Co., Ltd. and its subsidiary, Xi'an Chunguang Trading Co., Ltd., amounts to 12.17 million yuan, which is a result of the acquisition [2][4] - The financial assistance does not affect the company's normal business operations and is not classified as a prohibited financial assistance under relevant regulations [2][7] Group 2 - As of June 30, 2025, the financial assistance includes 9.47 million yuan to Xi'an Chunguang and 2.7 million yuan to Xi'an Chunguang Trading, totaling 12.17 million yuan [4][5] - The company has established a repayment agreement with a 3.00% annual interest rate, with a repayment deadline set for December 31, 2025 [6][7] - The total amount of financial assistance provided represents 2.50% of the company's most recent audited net assets [7]